



## Therapeutic Advantages of highly standardized Boswellia Extracts

(Original article 2008 with a review and addendum 2011)

Ross Rentea MD


### Summary

Gum resin extracts of frankincense (*Boswellia serrata*) have been used for centuries for the treatment of chronic inflammatory diseases. AKBA (3-O-acetyl-11-keto- $\beta$ - boswellic acid), a pentacyclic triterpene, is the most potent anti-inflammatory fraction of the boswellic acids. Principally among its many effects is the inhibition of the 5-LO enzyme and thus the suppression of its down stream pro-inflammatory leukotriene by-products. It is becoming increasingly clear that 5-LO metabolites are up-regulated in virtually all significant major chronic illnesses. Recent findings show that the 5-LO is expressed in practically all underlying inflammatory pathogenesis, in classical conditions like asthma, colitis or joints diseases but also in atherosclerosis and other cardiovascular diseases; bone resorption and osteoporosis; skin illnesses such as atopic dermatitis, psoriasis, acne and contact dermatitis; cancers such as pancreatic, bladder, breast, brain and prostate; neurological degenerative ailments and migraine; venous stasis; allergies and allergic sinusitis, etc. More conditions are regularly added. Inhibition of the 5-LO pro-inflammatory lipid mediators will be increasingly seen as part of the standard-of-care. The necessity of appropriately suppressing the 5-LO originating inflammation has been tackled largely unsuccessfully by the pharmaceutical industry up to now. Besides boswellic acids (BA's) there are currently no other comparably potent and risk free natural 5-LO inhibitor on the market. Boswellic acids are 5-LO inhibitors but the use of unpurified boswellia serrata extracts (BSE's) with a low 2-3% AKBA concentration have proven to have limitations and in some conditions outright contra-indications. Newly available BSE's standardized to 90% pure pharmaceutical grade AKBA avoid the previous pitfalls and augment clinical success rates. Nutritional supplementation with pharmaceutical grade BSE containing a high percentage of the AKBA fraction avoids the necessity of simultaneous exposure to high levels of other beta boswellic acids which can actually increase platelet aggregation and other paradoxical inflammatory reactions if a hyper-coagulable state exists. A daily dosage of 100-300 mg AKBA is the minimum required intake in order to achieve the effective therapeutic plasma levels suggested by clinical and laboratory studies. Various nutritional modalities are described here that have been found to significantly increase the absorption rate and bio-availability of AKBA. Most of the current boswellia formulations have a low AKBA content that cannot achieve the required blood levels of AKBA in a practicable

manner. The new BSE purified for a maximally high concentration AKBA fraction promises a leap in the hoped for clinical response rate. The ever expanding understanding of the benefits of suppression of the 5-LO enzyme will lead to an exponential increase in the diversity of indications for the use of highly standardized BSE.

Keywords: Boswellic acids, Boswellia serrata extracts, 3-O-acetyl-11-keto- $\beta$ - boswellic acid, 90% AKBA, 5-lipoxygenase, 5-LO, Leukotrienes,


**Fig.1 AKBA structure**



**This entire document is copyrighted by True Botanica and may not be reprinted or distributed by any means without the express permission of the company.**

### Abbreviations used

5-LO	=	5-Lipoxygenase
AA	=	Arachidonic Acid
AIA	=	Aspirin Induced Asthma
AKBA	=	Acetyl- 11-keto- $\beta$ -boswellic acid
AKBBA	=	same as AKBA
BA	=	Boswellic acid
BSE	=	Boswellia serrata Extract
COX	=	Cyclooxygenase
CystLT	=	cystenyl leukotriene
CSCR	=	Central Serous Chorioretinopathy
EIA	=	Exercise induced Asthma
ERK	=	Extra-cellular signal-regulated kinase
FLAP	=	5 lipoxygenase activating protein
HETEs	=	Hydroxyeicosatetraenoic acids
HLE	=	Human Leukocyte Elastase
IC <sub>50</sub>	=	Inhibitory Concentration 50%
IKK	=	I $\kappa$ B kinase
IL	=	Interleukin
LT	=	Leukotriene
MAPK	=	Mitogen activated protein kinase
MMP -2	=	Matrix metalloproteinase -2
NF $\kappa$ B	=	Nuclear Factor $\kappa$ Beta
PAF	=	Platelet Activating Factor
PMNL	=	Polymorphonuclear Leukocytes
PT	=	Pentacyclic triterpenes
PUFA	=	Polyunsaturated fatty acid
ROS	=	Reactive oxygen species
RSV	=	Respiratory Syncytial Virus
sLT	=	sulphido-leukotriene
TNF $\alpha$	=	Tumor necrosis factor $\alpha$
VEGF	=	Vascular endothelial growth factor
WBC	=	White Blood Cells



Generation of arachidonic acid metabolites and their roles in inflammation.

**Fig. 2**  
The role of the 5-LO pathway in the generation of leukotrienes (LT's).

(after, Robbins and Cotran, Pathologic Basis of Disease, 2005, 7<sup>th</sup> Edition)

## Introduction to Boswellic Acids

The gum resin of *Boswellia serrata*, frankincense, has a number of components including oils, ( $\alpha$ -Thujene), terpenols, monosaccharides and most importantly terpenes. Major research has centered on the components belonging to the pentacyclic triterpene group of compounds considered to be most bio- active. PT's are mainly synthesized in higher plants, due to the highly complex requirements for their synthesis. They exhibit a variety of profound effects such as being anti-inflammatory, anti-nociceptive, anti-oxidant, anti-bacterial, cancer drug sensitizing, cardio-protective and insulin resistance lowering.(1-5) HPLC procedures have shown over fifteen specific PT compounds in boswellia species, such as  $\alpha$  - and  $\beta$ -boswellic acid, 3-O-acetyl- $\beta$ -boswellic acid, 3-O-acetyl-11-keto- $\beta$ -boswellic acid,  $\alpha$ -amyrin,  $\beta$ -amyrin, lupeol, 3-epi- $\alpha$ -amyrin, 3-epi- $\beta$ -amyrin, 3-epi-lupeol,  $\alpha$ -amyrenone,  $\beta$ -amyrenone, lupenone, lupeolic acid and 3-O-acetyl-lupeolic acid, tirucallic acid, and others. (2)

The general composition of the dry *Boswellia serrata* extract of the gum resin shows approximately 50-60% various  $\alpha$  -and  $\beta$ -boswellic acids, of which roughly 1-3% of the total are the most bio-active AKBA fraction.(6, 7)

The lipophilic fraction AKBA, with a beta configuration, has been shown, by various pharmacological studies, to possess superior anti inflammatory properties over the  $\alpha$  configured isomers. (3)

With the current commercial availability of a BSE purified to 90-99% AKBA, the work done to more fully understand this fraction is steadily gaining in importance.

## Traditional and Non-Conventional Views on the Use of BA's

*Boswellia serrata* is indigenous to Africa, India and the Arabian Peninsula. The fragrant resins have been used since Antiquity in incense and embalming liquids. In ancient Ayurvedic texts the gum resin is noted for its healing properties on fever, skin diseases, rheumatism, respiratory diseases including laryngitis and cough with copious amounts of sputum, liver disorders, ringworm, boils, strengthening of teeth, healing eye inflammations, enhancing the growth of hair, improving appetite, wound healing, soothing mouth sores, improving diarrhea, general restorative, tonic effects and more.

In more recent times Rudolf Steiner PhD has pointed out the significant energetic healing properties of these resins in both adults as well as in the developing infant. He especially emphasizes the beneficial effects of these resins on breast milk quality, the developing brain of the young child and their overall ability to maintain "a healthy spirit in a healthy body." (Cosmic Workings in Earth and Man, R. Steiner, R. Steiner Publishing Co., London, 1952.)

## **Review of Human Clinical and Animal Studies with BA's and specifically the AKBA fraction**

Multiple studies from the 1990's to the early 2000's show generally very positive results with BA's. (8) (9-11, 11-27) The main areas of study-- arthritis, cancer, asthma/allergies and inflammatory bowel disease will be briefly reviewed.

### **Arthritis**

#### Specific findings

Poeckel (28) reviews in detail many human and animal studies done with a variety of boswellia preparations. His main findings are summarized briefly here.

The first scientific reports on the analgetic properties of BA's came out more than 35 years ago. Animal studies demonstrated the anti-inflammatory activity of BA's and the prevention of progressive joint collagen destruction due to the finding of decreased levels of inflammatory markers. More recent animal studies demonstrated reduced carrageenan or dextran induced edema, reduced papaya latex- induced rat paw inflammation, reduced intermittent lameness, local pain and stiff gait in osteoarthritic dogs, etc. A study of 2005(10) proved that strong anti-arthritis changes were accompanied by significantly suppressed TNF $\alpha$  and IL-1 $\beta$ .

In human studies the results were equally encouraging. Kulkarni(17) evaluated 42 patients with osteoarthritis recording increased walking distance, less knee stiffness, etc. However, in one multi center study no demonstrable statistically relevant clinical improvements were noted. (29) It should be noted, however, that patients received only a low BSE dose. No comments were offered whether a higher dose may have changed the outcome.

#### General conclusions:

- BA's lessened severity of pain in joints;
- BA's diminished knee swelling and knee flexion;
- BA's increased duration of walking distance.

### **Inflammatory bowel disease**

#### Specific findings

Poeckel (28) reviews in detail the human and animal studies done with a variety of boswellia preparations in the IBD model. His main findings are summarized briefly here. Animal studies showed protective effects specifically of AKBA in toxin induced hepatitis and ileitis. AKBA also significantly blunted experimental mouse colitis and prevented typical inflammatory cell reactions like recruitment of adherent leukocytes and platelets into inflamed colonic venules. AKBA also largely prevented the P-selectin up-regulation. These effects were similar to those in mice treated with corticosteroids.(30)

Recently, BA's were shown to prevent experimental diarrhea and to normalize intestinal motility without slowing down the rate of transit when given to control animals. (8)

In a human study patients with colitis, grade II and III, had an 82% remission rate when treated with BA's as opposed to 75% of those in the control sulfasalazine group.

In another study 14 BA's treated patients, out of a total of 20 patients, went into remission, as opposed to 4 out of 10 patients in the control sulfasalazine group.

General conclusions:

- BA's improved clinical well being in patients with IBD;
- BA's improved stool properties, microscopy of rectal biopsies, hemoglobin and other blood parameters, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils, and the Crohn's disease activity index.

## **Cancer**

Specific findings

Poeckel (28) reviews in detail human and animal studies done with a variety of boswellia preparations in cancer model set ups. Some of his findings are summarized briefly here. Topical application of BA's prevented or slowed tumor cell promotion when animals were fed a diet containing 0.2% by weight AKBA, clearly showing anti-neoplastic qualities of BA's. (31)

Another study showed that BSE's influenced glioma cell growth. AKBA could still be detected in the brain 3 hours after oral administration of a 240mg/kg of BSE to rats. (32)

In a human study, 19 children with intra-cranial tumors received palliative therapy with BSE. Although no anti-neoplastic effects were seen, 8/19 children experienced some significant clinical improvement.

In 2002, the European Agency for the Evaluation of Medicinal products (EMEA) released a positive opinion for orphan designation of BSE for the treatment of peritumoral edema derived from brain tumors.

General conclusions:

- BA's improved general health status, muscular strength, weight gain in cancer patients;
- BA's decreased neurological symptoms in patients with intra-cranial tumors;
- BA's decreased edema of brain tumor patients.

## **Allergy and Asthma**

Specific findings

Poeckel (28) reviews in detail human and animal studies done with a variety of boswellia preparations. His findings are summarized briefly here.

In several studies animal passive paw anaphylaxis reaction and mast cell degranulation was reduced.

A human clinical double blind study was done on forty patients with chronic asthma. They were given 300 mg three times daily of a BSE for 6 weeks. 70% of patients showed improvement by the lowering of attack frequency, lowered eosinophilic counts, disappearance of dyspnea, rhonchi and an increase in pulmonary function, such as increase of FEV 1 and FVC. In the control group only 27% of patients showed improvement.

General conclusions:

- BA's improved general status in chronic asthma patients;

## **AKBA Activity at the Cellular/Molecular Level**

The majority of the most recent studies and reviews have been highlighting the pre-eminent role of the AKBA fraction over the other  $\beta$ -boswellic acids. (27, 33, 33-42) (43-48) (24, 25, 30, 49, 50) (26, 27) (51) (52) (3, 53) ;(54, 55) (56) (57)

AKBA has been shown to:

- impair leukocyte infiltration and antagonize humoral immune response;
- suppress the classical and alternative immune complement pathway;
- inhibit mast cell degranulation;
- suppress LPS-induced NO production in peritoneal macrophages, effects that confer a reduced risk of anaphylaxis;
- suppress LPS mediated TNF $\alpha$  induction in monocytes;
- inhibit TH1 cytokines (IL-2), typically elevated in rheumatoid arthritis;
- inhibit interleukin IL-1 $\beta$ ;
- inhibit in a non-redox, non-competitive fashion the 5-Lipoxygenase enzyme (discussed in more detail below), and thus its LT's producing pathway;
- decrease intracellular basal Ca<sup>2+</sup> in monocytic cells, and suppress the activation of p38 MAPK, both of which being pro-inflammatory signal transducers
- inhibit the NF $\kappa$ B pathway and NF $\kappa$ B regulated gene expression leading to TNF $\alpha$  suppression apparently by direct inhibition of IKK's;
- inhibit the expression of the pro-inflammatory effectors (matrix metalloproteinases) and adhesion receptors;
- inhibit the human leukocyte elastase;
- suppression the P-selectin up-regulation and leukocyte platelet adherence in colitis models;
- inhibit topoisomerase I and II, thus leading to blocked proliferation and cell differentiation;
- inhibit DNA, RNA and protein synthesis in HL-60 cells;
- induce apoptosis in selected cancer cell lines through the central mediation of caspase-8 which in turn activates the "executor" enzyme caspase -3;
- inhibit PKB/Akt phosphorylation and p38 MAPK as well as ERK 1/2 phosphorylation and cell motility in meningioma cells;
- non-selectively inhibit the drug metabolizing CYP enzyme family;
- inhibit the activity of P-glycoprotein in leukemia cell lines (only AKBA, but not BA's lacking the 11-keto group);
- significantly reduce PAF in CCl<sub>4</sub> induced hepatic liver fibrosis.

## **Specific Inhibition of the 5-LO by AKBA**

### **The Inflammatory Cascade**

In answer to specific external stimuli, and after the appropriate signal transductions, the cell membrane lipid AA – a 20 carbon PUFA- is rapidly formed in order to generate lipid mediators that lead to functional inflammatory processes. As seen in Fig.2 an increase in intra cellular Ca<sup>2+</sup> and various kinases is necessary for the activation of the inflammatory cascade. Two enzymes – the 5LO and the COX (1 and 2) – synthesize the eicosanoids, principally prostaglandins and leukotrienes, both of which are involved in virtually all inflammatory responses. Of main interest

here is the lipoxygenase pathway whose products lead to vascular permeability, chemotaxis and leukocyte adhesion, as well as bronchoconstriction. Particularly LTB<sub>4</sub> is a powerful chemotactic agent that leads to activation of functional neutrophil responses, release of lysosomal enzymes, generation of ROS and platelet aggregation. LT's are several orders of magnitude more potent than histamine in increasing vascular permeability and causing bronchospasm.

When a variety of WBC's are activated, (principally among them macrophages and lymphocytes, but also endothelium, epithelium and connective tissue cells), cytokine proteins (such as TNF $\alpha$ , IL-1, etc) are produced and lead to the augmentation of the inflammatory reactions (fever, loss of appetite, etc.) A further consequence of the activation of inflammatory cells is the enhanced production of NO, a potent vasodilator with multiple pro-inflammatory activities. (Robbins and Cotran, Pathologic Basis of Disease, 2005, 7<sup>th</sup> Edition)

### **How is 5-LO bio-regulated?**

The enzyme is mainly restricted to myeloid cells, like macrophages, granulocytes, etc but can also be expressed in human skin keratinocytes, Langerhans cells or brain cells. A number of intermediates like phospholipase A, membrane bound FLAP, and others are needed for biosynthesis. Higher intracellular Ca<sup>2+</sup> levels increase the affinity of 5-LO toward AA. Similarly oxidative and genotoxic stress results in a higher level 5-LO activation. Of great interest should be the fact that 'priming' agents such as cytokines, Epstein-Barr virus (!) and others do not in themselves lead to activation of 5-LO and its resultant LT's, but subsequent stimulation of the cells with pro-inflammatory agonists leads to a strongly increased production of LTs! (58-60)

### **5-LO Inhibition**

In general pharmacological inhibition of 5-LO and LTs can be achieved by the following main strategies:

1. Inhibition of PLA<sub>2</sub> enzymes, leading to a lesser AA substrate availability;
2. Inhibition of FLAP.
3. Direct inhibition of 5-LO;

Inhibition of PLA<sub>2</sub> enzymes would theoretically prevent formation of all eicosanoids. In clinical studies, however, glucocorticoids, known inhibitors of PLA<sub>2</sub>, are ineffective in suppression of LTs.

FLAP inhibitors have also proven not to be a viable solution. There are a number of synthetic FLAP inhibitors that have been tested, but they have shown to be 50 to 200 times less potent in clinical situations than in the *in vitro* isolated leukocytes.

The direct 5-LO inhibition can be categorized into three modes of action:

1. Redox-active 5-LO inhibitors, which act by reducing the iron at the active site. 5-LO is a di-oxygenase that catalyzes the incorporation of molecular oxygen into liberated AA. 5-LO contains a non-heme iron at the active site in the ferric form (Fe<sup>3+</sup>). This forms the basis for the inhibitory action of some 5-LO inhibitors which convert the ferric to the ferrous form (Fe<sup>2+</sup>). (61-64) Agents discovered in this direction are not currently used due to their severe side effects. (65)
2. Iron ligand inhibitors chelate the active site iron. An example in this category would be the drug zileuton which has been shown to improve asthma but has demonstrated only a small benefit in allergic rhinitis, arthritis and inflammatory bowel disease and no effect in ulcerative colitis. (66)
3. AKBA belongs to the third group of so called non-redox inhibitors of 5-LO. It has a unique mechanism of action that is gradually being better understood. It acts directly on 5-LO at a site that is different from the catalytic AA binding cleft. Its lack of any significant side effects, high safety level and favorable toxicological studies, as well

extensive traditional and modern clinical use across many divergent pathologies make this an ideal 5-LO inhibitor.

AKBA was confirmed as the most active boswellic acid fraction to inhibit the 5-LO with an IC<sub>50</sub> value in the range of 1.5-8 μM. (67) (68-72)

The AKBA concentrations needed for complete 5LO inhibition vary greatly depending on the experimental set up and type of cells studied. In some intact animal cell studies the IC<sub>50</sub> was around 8μM while in cell free assays it could go up to 50μM! This suggests that the potent LT suppression is due also to interference of AKBA with other cellular events required for the activation of 5LO. (28)

AKBA interferes with the activity of the 5-LO by acting at a selective binding site for PTs on the 5-LO. This site is different from the AA-binding site of the 5-LO. The PT ring system is crucial for binding to the selective effector site, whereas functional groups like the 11-keto moiety are essential for the 5-LO inhibitory activity. (71-73)

Several unexpected findings point to an even more complex picture of 5-LO inhibition by AKBA. In several studies, contrary to expectations, after BA's were given to stimulated PMNL cells there occurred an increase in Ca<sup>2+</sup> mobilization, activation of ERK2 and MAP kinases, as well as an up-regulation of 5LO activity instead of a down regulation.(68, 69)

Poeckel (28) suggests the following as explanation for these observations that run contrary to the predominant body of findings. He postulates that the mentioned events potentially lead to a temporary elevation of reactive oxygen species (ROS) production which in turn irreversibly inactivated the redox-sensitive 5LO.

It is becoming increasingly clear that the interference of BA's with the inflammatory cascade and the 5-LO is strongly dependent on the biological situation involved, the structure of the BA's- i.e. the presence of the keto moiety or not- etc. AKBA may lead to cell stimulation in un-stimulated cells but on the other hand may prevent subsequent activation of cells in inflammatory conditions such as when challenged by an additional ligand like TNFα .(28, 50, 53, 74, 75) .(69)

## **Recent Insights into the Therapeutic Applications of 5-LO Inhibition**

### **General observations**

5-LO is the key enzyme in the biosynthesis of LT's. These pro-inflammatory mediators are potent chemotactic and chemokinetic mediators stimulating the immigration and activation of granulocytes, leading to adherence of granulocytes to the vessel walls, degranulation of mast cells, and the release of superoxide. They are connected to increased interleukin production and neutrophil dependent hyperalgesia, cause vascular permeability and smooth muscle contraction. Cys-LTs lead to smooth muscle contraction, plasma extravasation, recruitment of neutrophils, and vasoconstriction. They are up to 1000-fold more potent than histamine. Animal studies with genetically disrupted 5-LO genes showed significantly reduced inflammatory responses to a number of noxious stimuli especially arachidonic acid caused inflammation. In view of the high AA containing modern Western diets, these results are epidemiologically very significant. (76) Multiple other studies have established a significant role for LT's in inflammatory diseases such as arthritis, inflammatory bowel diseases and asthma. (77-79)

In another comprehensive review Rubin(80) points to the central role that 5-LO and its leukotriene metabolites play in chronic severe exercise and in the aspirin induced forms of asthma, COPD, allergic rhinitis, idiopathic pulmonary fibrosis, ischemia related organ injury, and atopic dermatitis.

Recent studies have implicated LT's and other 5-LO products in unexpected pathophysiological illnesses such as the bone resorptive metabolism of osteoporosis, the atherogenic processes of the

cardiovascular system, atopic and hyperproliferative skin diseases such as dermatitis and psoriasis, and the proliferation as well as survival of tumor cells, and multiple other conditions. Studies confirm the role of 5-LO products in ear inflammation and peritonitis. (81)

Interestingly, the global inhibition of 5-LO has proven to be more efficacious than the partial inhibition of the 5-LO pathway through either LT antagonists, LT receptor antagonists or LT competitors.

Examples of the LT's induced cellular changes leading to pathological disease manifestations are given in Table 1. Not surprisingly a consensus is emerging that pharmacological inhibition of 5-LO and its metabolites represents an important potential for the treatment of a host of conditions. The broad range of applications is obvious from Table 2.

### **Cardio-vascular Diseases**

The role of the 5-LO in atherosclerosis is particularly interesting.

Atherosclerosis, a major cause of morbidity and mortality, is now seen as an inflammatory fibro-proliferative disease. LT receptors are abundantly expressed in atherosclerotic lesions in the aorta, heart and carotid artery. In fact the presence of high expression of 5-LO, FLAP, and leukotriene hydrolases correlate well with high plaque instability. (82) Review of animal and human data suggest that 5-LO and its metabolites are up regulated in vessel walls, macrophages, dendritic cells, foam cells, mast cells, and neutrophils. Recent studies clearly have identified the 5-LO and/or FLAP gene as a risk factor in such as cardio vascular diseases as stroke and myocardial infarction. (82-87)

A survey of 470 subjects identified to have a gene variant leading to an increased expression of 5-LO demonstrated a significant increase in carotid artery intima-media thickness. Dietary intake of fish oils, which reduce the production of LTs blunted the genotype effect. Another recent survey of subjects from Britain and Iceland, with higher than normal 5-LO expression, showed, double the usual rate of heart attacks. Mice genetically lacking the 5-LO gene showed a dramatic 26 fold reduction in aortic lesions. (88-90) These studies suggest that 5-LO inhibition would be a valuable preventative measure in CV disease.

Significantly increased urinary LT levels were found in patients following admission for acute myocardial infarction.

Elevated levels of LTs were also found in patients with unstable angina.

LTs are also involved in sickle cell disease and septic shock. Taken together these studies demonstrate that there is a significant benefit to treat patients suffering from ischemic injuries and the resulting organ damage by eliminating inflammatory events through 5-LO control. (91-94)

Recently, LT receptors have been shown to be expressed in the intimal hyperplasia of early atherosclerosis and in restenotic lesions after angioplasty. These findings emphasize the role that a 5-LO target could play in preventing restenosis after coronary interventions. (95)

### **Hypertension**

The 5-LO derived products cystLT and 12-HETE are vasomotor mediators with increased biosynthesis in various models of hypertension. LT's are involved in glomerular inflammatory injury. In addition it has been suggested that they might contribute to the vasoconstrictor, hypertrophic and mitogenic effects of angiotensin II. This might explain at least in part the vascular inflammatory complications associated with hypertension. (96-101)

### **Cancers**

Aberrant functioning and over-expression of 5-LO pathway products may contribute to cell proliferation, evoke angiogenesis and effect survival of particularly prostate and pancreatic cancers. Making these cellular signals part of the therapeutic targets, either alone or better in

combination with other modalities has been shown to slow tumor progression, reduce tumor cell invasiveness and tumor cell motility and decrease tumor angiogenesis. (102-104)

Cigarette smoke is known to cause an inflammatory response in the colon that can lead to colon adeno-carcinoma. The mechanism seems to be via an up-regulation of 5-LO induced protein expression accompanied by up-regulation of metalloproteinases-2 and vascular endothelial growth factor. 5-LO inhibitors reduced the incidence of adenomas, angiogenesis and MMP-2 activity and VEGF. The results strongly suggest that cigarette smoke induced 5-LO expression leading to colon adenoma formation can be reduced by 5-LO inhibitors. (105, 106)

5-LO and its metabolites have been found to have an increased expression in lung cancers and to inhibit apoptosis as well as contribute to cell proliferation. These advances in the understanding of the molecular biology of lung cancer has led to the conclusion that 5-LO pathway inhibitors should be part of the chemoprevention armamentarium in these illnesses. (107)

### **Respiratory illness**

Pulmonary damage in cystic fibrosis is mediated largely by 5-LO pathway generated eicosanoids and leukotrienes released by PMNL's. A reduction in pro-inflammatory mediators was deemed to substantially lessen the damaging tissue inflammation. (108)

RSV infection causes significant morbidity both in the adult but especially in the pediatric population. By the age of three most children have been infected at least once. The typical symptoms of runny nose, copious mucous discharge, cough, progression to wheezing and potential respiratory distress can lead to hospitalization in 1-2% of all cases. The illness can last for weeks and can exacerbate asthma. The mechanism for viral damage is not well understood and no specific therapy is indicated. Interestingly, however, the 5-LO and the LT's discharged from mast cells are significantly increased in the inflammatory discharge and a potential role for 5-LO inhibition is thus given. (109) (110, 111)

Pneumococcal otitis media is associated with the production of high levels of LT's. The presumptive mechanism seems to be that the pneumococcus bacteria activates the 5-LO pathway by up-regulating the expression of the  $\epsilon$ PLA2 and 5-LOX genes. This in turn may stimulate the production of proteins leading to the formation of fluid in the middle ear. (112) This may explain the anecdotally observed benefit of supplementation with BA's in children with various upper and lower respiratory illnesses.

Rhinovirus infections can cause cough, wheezing and bronchial hyper-responsiveness, in otherwise normal individuals. Bronchial aspirations in these patients demonstrated marked inflammation characterized by markedly enhanced expression of 5-LO pathway proteins. (113) The LTs involvement in severe asthma, especially AIA and EIA, is becoming well established. 5-LO inhibition has been demonstrated to significantly increase forced expiratory volume and morning and evening peak expiratory flow rate. Because inhibition of the 5-LO pathway is so highly effective in both AIA and EIA their use has been recommended as meriting first line therapy status in both disorders. (80, 114-117) Patients with severe asthma and frequent asthma exacerbations may also be good candidates since there is a common association with neutrophil predominance and there is pronounced airway remodeling. (118-123) An additional highly significant advantage to 5-LO inhibition is that it fills the gap in anti-inflammatory coverage of inhaled glucocorticoids. (124)

Trials of 5-LO inhibitors in allergic rhinitis and sinusitis showed that 72% of participants had a positive response of symptom reduction and 50% experienced reduction of nasal polyps. (125-128)

### **Osteoporosis, Bone Metabolism and Joint Diseases**

A connection between 5-LO, LTB<sub>4</sub>, other arachidonic acid derived eicosanoids and osteoporosis is becoming more apparent.(129-131, 131, 132)

Bone resorption requires cooperation between osteoclasts and mononuclear accessory cells. 5-LO metabolites have been shown to stimulate this process.(133) Among the 5-LO generated LT's especially LTB<sub>4</sub> seems to activate osteoclasts and cause surface erosion.(129)

Various animal models using experimental inhibition of 5-LO have prevented loss of bone mass in rodents, with a concomitant increase of femur and humerus volume, density, femur calcium levels and ash weight.(134) (135) (132)

### **Skin Diseases**

5-LO and its lipid metabolites, the LT's, have been increasingly recognized as having a pivotal role in dermatologic disorders like psoriasis, acne and atopic dermatitis. (59, 60) In all three conditions reducing the levels of LTs results in significant lessening of edema, pruritis, redness and reduces responses to antigens. (136-138) (139-142) (143-146)

In atopic dermatitis changes related to LT's, like an elevation of eosinophils and increased production of cytokines IL-4, IL-5, IL-13, can be controlled with means that suppress LT's. Circulating leukocytes in atopic dermatitis show an increase in LTB<sub>4</sub> and LTC<sub>4</sub>. The characteristic erythema is probably mediated via cyst-LT's. Skin cell production of LT's was increased almost 5-fold with antigen challenge. In 5 of 7 clinical studies a significant reduction in disease activity and symptom severity was noted with the use of 5-LO inhibitors.

Considering that acne is a complex inflammatory disease, it is not surprising that LT's play an important pathological role here too. LTB<sub>4</sub> and LTC<sub>4</sub> have been shown to have a mitogenic effect on keratinocytes. Sebocytes also express both 5-LO and LTs. Pharmacologic studies also support the idea that 5-LO and its eicosanoid metabolites have a significant role in acne. 5-LO inhibitors have been shown to be therapeutically beneficial by reducing the severity and frequency of acne lesions, and reducing sebum production and the total output of sebum lipids and sebum free fatty acids.

### **Neurological Diseases**

Clinical observations have shown that patients with migraine taking LT receptor antagonists due to concomitant asthma have a lower migraine frequency. These observations are further enhanced by reports that these patients also become less sensitive to environmental triggers such as perfumes and other noxious stimuli. In an open label study the effect of LT antagonists on migraine sufferers was tested with the following results: 53% of subjects showed a greater than 50% reduction in the frequency of severe attacks; 41% showed a reduction of more than 60% in attack frequency. This was considered to be a clear indication that the 5-LO pathway was involved in the pathogenesis of migraine. (147)

More recently the postulate was examined that cognitive decline in aged brains is due to inflammatory CNS changes. Aging rats with significant cognitive defects in comparison to younger ones were examined by observing vascular leakage into the retina. Cognitive decline paralleled the LT's mediated retinal damage. (148)

### **Food Allergies**

Food allergies in both adults and children have seen an explosive increase in the last several years. As an example, in recent media news an Australian study is mentioned reporting a 12-fold (!) increase in food allergies since 1995 alone. Yet few new

therapeutic methods have been developed to effectively deal with these problems. (149)  
Are 5-LO mediators involved in food allergies?

Hyper-responsiveness to histamine is a key feature of a variety of pathological conditions, including food allergies and other intestinal conditions. Cysteinyl LT's have been implicated as mediators of increased histamine responses. Cyst LT's mediate histamine hyper-responsiveness by increasing histamine receptors in immunologically relevant cell types. (150)

In a study of 40 patients with adverse reactions after food intake LT's were shown to be significantly higher after antigen stimulation in the food sensitive group than in the control group. (151) Patients with chronic urticaria challenged with aspirin showed a significantly higher urinary excretion rate of LT's as compared to controls.(152)

Considering these novel insights into the role of 5-LO and LT's in the pathophysiology of these conditions one can expect to see an increased role for BA's in the first line therapy of these common complaints.

### **Venous Stasis**

The formation of varicose veins is more than a cosmetic disease. Venous blood stasis, vessel wall injury and a hyper-coagulable plasma state can lead to deep vein thrombosis and thromboembolism. Neutrophils are known to promote vascular injury and thrombosis following venous stasis. LT's are potent mediators of vascular injury and neutrophil chemotaxis. Animal studies demonstrated that 5-LO inhibition reduces deleterious neutrophil/vessel wall interactions. (153)

### **Gastric Diseases**

AA metabolites via the 5-LO pathway have been found to be pivotal mediators in Helicobacter pylori-induced inflammatory response. H. pylori stimulated the translocation of cPLA<sub>2</sub> from cytoplasm to nucleus and increased the biosynthesis of HETEs in the gastric epithelium. The administration of LOX inhibitors resulted in down-regulation of pro-inflammatory mediators such as IL-8 and TNF $\alpha$  in both H. pylori-infected gastric epithelial cells and macrophage cells. 5-LO inhibition could impose significant anti-inflammatory responses after H. pylori infection, based on the fact that H. pylori infection provoked gastric inflammation through metabolizing arachidonic acid by the 5-LO pathway.(154-156)

---

---

## **Table 1. Role of the 5-LO and its metabolites in creating pathological conditions**

### **Asthma**

- Reversible airway narrowing
- Hyper-responsiveness
- Eosinophil influx
- TH2 lymphocyte influx
- Basophil influx
- Neutrophil influx

- Edema
- Increased mucous production
- Decreased mucociliary clearance
- Goblet cell metaplasia
- Increased mast cell cytokines
- Collagen deposition
- Epithelial hypertrophy
- Myofibroblast hyperplasia

#### Allergic rhinitis

- Nasal congestion
- TH2 lymphocyte influx
- Edema
- Collagen deposition
- Subepithelial fibrosis
- Increased mast cell cytokines

#### COPD

- Neutrophil influx
- Macrophage influx
- Increased mucous production
- Goblet cell hyperplasia
- Collagen deposition
- Subepithelial fibrosis

#### Idiopathic pulmonary fibrosis

- Collagen deposition
- Subepithelial fibrosis
- Smooth muscle hyperplasia

#### Atherosclerosis

- Monocyte/macrophage influx
- Foam cell conversion
- Dendritic cell influx
- Mast cell influx
- T cell influx
- Intimal edema
- Smooth muscle cell hyperplasia

#### Ischemia reperfusion injury

- Edema
- Increased endothelial adhesion molecules
- Neutrophil influx

#### Atopic dermatitis

- Erythema
- TH2 lymphocyte influx
- Monocyte/macrophage influx
- Eosinophil/neutrophil influx
- Edema
- Collagen deposition

Fibrosis  
Acne vulgaris  
Seborrhea  
Keratinocyte proliferation  
Erythema  
T cell influx  
Mocyte/neutrophil/macrophage influx

---

---

**Table 2.**

**Conditions in which 5-LO and leukotrienes are excessively expressed.  
The use of AKBA is indicated here due to its potent inhibition of these pro-inflammatory metabolites.**

Acne  
Allergies  
Allergic conjunctivitis  
Allergic rhinitis  
Arthritis  
Asthma  
Atherosclerosis  
Bronchospasms  
Cancer  
Cellulites  
Cystic Fibrosis  
Dermatitis  
Ear inflammation  
Eczema  
Exercise induced shortness of breath  
Gastric ulcers/ H. pylori infection  
Gout  
Hepatitis  
Hyperlipedemia  
Inflammatory Bowel Disease  
Ischemic organ injuries  
Liver Cirrhosis  
Lupus Erythematosus  
Migraines  
Multiple Sclerosis  
Myocardial Infarction  
Neuro-degenerative Diseases  
Osteoarthritis  
Osteoporosis  
Pain syndrome  
Perennial Rhinitis

**Psoriasis**  
**Sinusitis**  
**Smoking**  
**Stroke**  
**Urticaria**  
**Venous Stasis/ Thrombosis**

---

## **Problems with boswellic acids**

Kiela reports of three studies with negative results. In one animal study BSE's were found to be ineffective in ameliorating murine colitis. He also reports that in a different in vitro set up, individual BA's rather increased the basal and IL 1- $\beta$  stimulated NF $\kappa$ B activity in the intestinal endothelial cells. In a third study BSE's showed hepatotoxic effects. (157)

Of the beta boswellic acids primarily BA's without the 11-keto moiety induced the pro-inflammatory ERK phosphorylation connected to substantial mobilization of Ca<sup>2+</sup>. They also triggered liberation of endogenous AA, formation of p12-LO products, generation of thrombin and caused moderate aggregation of platelets. On the other hand AKBA suppressed survival signals along the ERK route in meningioma cells which could explain the anti-proliferative activities of AKBA. Inhibition of the classical and alternative complement pathway was reported only for high concentrations of BA's, for example  $\beta$ -BA's at IC<sub>50</sub> > 50  $\mu$ M (45, 47)

BA's overcome the problems of other 5-LO inhibitors most of whom, while identified as being active in vitro, have thus far not been suitable for clinical application, either because of poor bioavailability, specific side effects or loss of potency under oxidative conditions. This naturally increases the importance of BA's which have been shown to be of considerable value in human conditions.

Nevertheless not all BA fractions act in identical fashion.

For example, LT biosynthesis in intact cells was shown to be only weakly inhibited by BA's in the range of 15 to 40  $\mu$ g/ml. On the other hand, AKBA already inhibited 5-LO in the range of IC<sub>50</sub> of about 0.75  $\mu$ g/ml (1.5  $\mu$ M). (71, 72)

Moreover, very low concentrations of BA's – up to 10  $\mu$ g/ml – increased the 5-LO product formation to about 155% over controls (!) but reverted to the expected inhibition of 5-LO at higher concentrations of 20-40  $\mu$ g/ml, decreasing LT product synthesis by about 19%.

In contrast to the crude extracts, AKBA exerted no 5-LO increasing activity in low concentrations up to 0.25  $\mu$ g/ml, and starting with concentrations of 0.5  $\mu$ g/ml acted in an inhibitory manner.

Again in contrast to the simple crude extracts, AKBA inhibited the 5-LO completely with an IC<sub>50</sub> of about 2  $\mu$ M whereas the action of the extracts was only 80-85% complete.

It seems that the action of crude extract BA's is biphasic in nature with both inflammatory and anti-inflammatory results depending on the concentration, while AKBA has a purely inhibitory property. These findings underlie the necessity of standardization of boswellia extracts if consistent results are hoped to be obtained. (158)

Poekel (159) presents data in his paper on the influence of BA's on human platelets. He reports that  $\beta$ -boswellic acids caused a pronounced mobilization of Ca<sup>2+</sup> from internal stores and induced the phosphorylation of p38 MAPK, ERK2 and Akt. These pro inflammatory changes were concentration dependent and the magnitude of the responses was comparable to those

obtained after platelet stimulation with thrombin or collagen. In higher concentrations,  $> 10\mu\text{M}$ , liberation of AA and platelet aggregation can occur. In contrast to  $\beta$ -BA's the 11-keto- $\beta$ -boswellic acids, AKBA, evoke only moderate  $\text{Ca}^{2+}$  mobilization, but fail to induce phosphorylation of ERK2 or Akt, and do not cause platelet aggregation or significant generation of thrombin. Since  $\beta$ -BA's induce the changes at concentrations comparable to those seen in human plasma levels the findings might raise the concern that under the right hypercoagulatory circumstances thrombus formation may occur. Nevertheless, while certain signaling components are induced, others are not, so that the process must not lead necessarily to the induction of a full platelet aggregation function. Still the advantage of using purified AKBA fractions when higher concentrations are desired for clinical purposes becomes evident.

## Dosage questions in the Administration of AKBA

### Bioavailability

To be effective a product must be demonstrated to be bioavailable. Several studies have looked at the plasma levels of BA's and AKBA following single or multiple oral intakes.

On a rudimentary basis this was proven in rats (32) where measurable levels of AKBA were found in the brain after 3 hours following a single oral administration dose of 240 mg/kg of dry BA's extract.

In a human study the plasma level of AKBA was  $0.1\mu\text{M}$  after oral intake of 4x786mg unpurified *B. serrata* extract. (28)

### IC<sub>50</sub> values

Inhibition of the classical and alternative complement pathway was reported only for high concentrations of BA's f.ex.  $\beta$ -BA's at  $\text{IC}_{50} > 50\mu\text{M}$  (45, 47)

AKBA, a non-redox inhibitor of 5LO, was found to have an  $\text{IC}_{50}$  value determined at  $1.5\mu\text{M}$ . (70) up to  $8\mu\text{M}$  (68-71, 73)

AKBA potently suppressed p12-LO product formation ( $\text{IC}_{50} = 15\mu\text{M}$ ), with higher potency for p12-LO in cell free assays as compared to crude 5-LO. (28, 74)

AKBA inhibits the HLE at levels of  $\text{IC}_{50} = 0.9-15\mu\text{M}$ . (19)

In monocytic cells AKBA reduced the phosphorylation of ERK2 at a concentration of  $3\mu\text{M}$ . (28, 53, 74)

Different BAs, with AKBA being the most potent derivative, were found to inhibit DNA and RNA in HL-60 cells with  $\text{IC}_{50}$  values ranging from  $0.5 - 7.1\mu\text{M}$ . Apoptosis of various cancer cell lines could be achieved with AKBA concentration  $> 10\mu\text{M}$ . (31, 35, 54, 55, 160-167)

### Pharmacokinetics

A basic pharmacokinetic study was done by Sharma et. al. (168) on BA's and AKBA. This was helpful in order to begin elucidating the behavior of BA's, their bioavailability and optimal dosing. Twelve healthy volunteers were given a one time dose of 333mg of a BSE containing 65% organic acids, minimum 40% boswellic acids, and 2% AKBA.

The plasma levels were assessed prior to and hourly after drug administration. The peak plasma levels of BSE ( $2.72 \times 10^{-3} \pm 0.18\mu\text{moles/ml}$ ) were reached at  $4.5 \pm 0.55$  hours. The apparent volume of distribution was very large at  $142.87 \pm 22.78\text{ L}$ . The elimination time was  $4.5 \pm 0.55$  hours. This elimination time suggests that the drug should be given at an interval of approx. 6 hours. They calculated that the steady state would be achieved in approximately 30 hours.

One can make some interesting observations looking at their data. At six hours post drug the maximal plasma levels of AKBA of the 12 subjects were: 1.56; 1.41; 1.84; 2.18; 1.75; 2.73; 2.39; 1.79; 1.20; 0.99; 0.86; 3.18 ( plasma concentration  $\times 10^{-3}$ ( $\mu$ moles/ml). This means that no more than 50% of the subjects reached the 1.5 $\mu$ M concentration that all the other studies demonstrated is the minimum needed for an effective inhibitory concentration. Going above the usually given daily 1g of a BSE with the customary 2-3% AKBA might help capture a lot of the so called therapeutic failures which may simply represent an under-dosing of test subjects or patients.


### **What is then a desirable range for an oral dose of AKBA?**

Ideally, one would need a daily intake of at least 150 mg of pure AKBA(!) in order to be in the minimally effective concentration range of 2 $\mu$ M .

This sheds an interesting light on the success rate, or rather lack thereof, of studies where amounts of 3,600 mg daily of unpurified BSE's (with AKBA contents around 2-3%) were given. With the most generous assumptions this would result in a 100 mg daily pure AKBA dose, right at the border of effectiveness. In the current "real world" practice even lower daily doses of only 1,000 mg unpurified BSE's are given again with correspondingly low success rates.

### **Enhancing Therapeutic Blood Levels of AKBA**

The bio-available plasma levels of various BA's and especially AKBA were shown to be significantly enhanced by concomitant administration of a fat containing meal. (7) 786 mg of a dry BSE containing 28.71 mg, 3.7%, AKBA were administered to healthy volunteers and plasma levels recorded at hourly intervals post ingestion. Various boswellic acid fractions were analyzed. For AKBA, the data (as also seen in Fig. 3) shows that the mean concentration went from 6.0 to 28.8 ng/ml. Overall, the area under the concentration time curve under high fat meal conditions compared to fasted conditions was increased by 414%, and the maximal plasma concentration under fed conditions compared to fasting increased by 380%. The meal consisted of fried eggs, bacon, milk and French fries. The authors (7) interpret the improved results accompanying this meal to suggest that the benefit was due to an increased stimulation of bile acids.



Plasma concentration of AKBBA after a single oral dose of BSE of 786mg, containing 28.71 mg AKBBA, under fasting conditions and then concomitant with a high fat meal. (after Sterk, V. et al, 2004) (7)

**Fig. 3**

Clearly there are more desirable ways to improve bile secretion than a highly atherogenic meal. Several animal studies have objectified the stimulant action of food spices on the enhanced secretion of bile acids, as well as improved function of pancreatic enzymes and the terminal digestive enzymes of the small intestine. (170-172)

In these experiments the following spices have proven to be most stimulatory on bile acid outflow, both biliary solids and bile acids: fenugreek, curcumin, coriander and particularly a mixture of coriander, pepper, turmeric, ginger and onion. The observed increase in bile acid flow and production was in the range of 50-80%.

### **Further means of improving 5-LO inhibition in general**

Various nutritional manipulations have been shown to enhance the effects of 5-LO inhibitors as such. Supplying the body with high amounts of Omega-3 fish oils is known to accomplish this goal. Additionally, altering the daily diet such that foods low in AA are eaten (meat, dairy products, eggs, etc) reduces the available AA load and thus automatically lowers the output of 5-LO metabolites, such as LT's.

H1 receptor antagonists like Allegra, Benadryl, etc. or their natural equivalents are employed to fight nasal congestion, eye and ear allergic reactions. The combination of an H1 receptor antagonist with a 5-LO inhibitor was found to have synergistic beneficial effects in animal models of allergy as compared to giving either drug alone. These insights may be valuable in the management allergic disorders, including asthma, allergic conjunctivitis, and allergic rhinitis. (173-180)

## Safety and Toxicology

Boswellic acids are generally regarded as safe (GRAS). Considering that BA's have been administered for thousands of years both orally and topically not to mention their inhalation as incense this in itself is not surprising. At high concentrations, unpurified BSE's have been reported on occasion to cause headaches or bowel irritation. This was easily remedied by temporarily suspending or reducing administration of the resin. Blood tests and tissue analysis have never revealed permanent toxic effects. Boswellic acids, even in concentrated forms, have never been shown to be skin irritating.

Recently (181), purified BA's were shown to be potent non-selective inhibitors of the drug metabolizing CYP enzyme family. Although the physiologic significance of this inhibition is not known to date the influence of this phenomenon on the pharmacokinetics of the other drugs should be kept in mind. To date no serious deleterious interactions with other prescription medications have ever been noted.

## Anecdotal Case Reports and Observations

### From the Paulina Medical Clinic

At our clinic, during the last three years, over 400 patients have received dietary supplements containing boswellia std. to 90% pure AKBA, either as sole intervention or in combination with other CAM modalities. The vast majority of cases involved fatigue, asthma, allergies, arthritis, pain syndromes, colitis and other inflammatory bowel diseases and allergic skin conditions. The results showed improved clinical outcomes in over 90% of all cases. Typical comments from patients were: "noted rapid relief response", "profound difference", or "best allergy season ever", etc. Essentially no adverse events were reported with the exception of a single case of gastric and intestinal irritation in a patient in whom very high doses were attempted (over 10 capsules /day). Incidentally, in similar cases of high dosing no such intolerance was seen. With our advancing understanding of the wide application palette of this substance we have started using boswellia std. to 90% pure AKBA in all the conditions noted in the tables above.

One particularly interesting case shall be presented here.

A 50 year old professional, male, was seen in the office presenting with visual disturbances in the left eye, hypertension of 170/100, and occasional upper abdominal "heart burn". Physical exam was unremarkable with the exception of mild obesity, BMI=28. The patient had been examined shortly before by an eye specialist who had found mild retinal changes consistent with central serous chorioretinopathy. CSCR is known to affect mainly high stress, "Alpha Type", males in the range of 30-50 years. The complaints are loss of sharpness in the eye field, distortions or trailing shadows after objects, sometimes light flashes or floaters. Some cases are quickly resolved, while others may lead to a chronic state. Hypertension, and, interestingly, gastric infection with *Helicobacter pylori* are frequent co-morbid conditions. Steroids given in any form can worsen the condition!

Neither conventional nor CAM therapies had been of any benefit up to this point. Surprisingly, within 24 hours of taking the first 50 mg capsule of boswellia std. to 90% pure AKBA, the patient reported a dramatic improvement in eye sight, the blood pressure lowered to 150/90 and the gastro-intestinal tract felt relieved. This improvement continued for the following observation time only to be negated again by stopping the purified AKBA supplementation. The patient is again on 50 mg x2 daily of AKBA and doing better.

### **From the Delafield Pediatrics Clinic**

Over 70,000 doses of AKBA have been dispensed from Delafield Pediatrics for a wide variety of conditions including asthma, allergic rhinitis, colitis, arthritis, RSV and acute infections, tendencies towards chronic and recurrent infections (pneumonia, sinusitis), complementary cancer support, breastfeeding support, general constitutional support for malaise and fatigue and others.

Patients have consistently reported favorable responses to therapy. Several examples follow:

M.J., a nine year old girl with a history of asthma and allergic rhinitis first came for evaluation for a history of persistent and recurrent symptoms including wheeze with intermittent respiratory distress, cough, and nasal congestion. She was on Flovent inhaler prophylactically and albuterol inhaler as needed (multiple times per week) and had required occasional rescue treatment with oral prednisolone. In addition she was taking Zyrtec syrup as needed.

After starting on 90% AKBA therapy, she was able to successfully wean off the Flovent over a 2-3 month period and her albuterol use decreased to once or twice per month. Over the last two years, she has maintained good control, sometimes going stretches of months without need for albuterol. Only once or twice has she required rescue treatment with Flovent inhaler for several days duration and has not required any subsequent oral steroid bursts. She rarely requires the addition of Zyrtec. She is in overall good health and the family is quite relieved and grateful for the changes.

D.I., a seven year old girl, presented with new onset Juvenile Rheumatoid Arthritis. Initial symptoms included severe right knee swelling and pain, varied toe swelling and pain, and hip pain. Over the initial months of the illness, affected areas included knees, hips, feet, hands, and back and she was also diagnosed with uveitis. After much of their own research, the family decided they wanted to pursue a more holistic therapy program.

Central to her therapeutic regimen has been treatment with 90% AKBA. On this therapy, she had some relief within 4-6 weeks and within 3-4 months was experiencing significant relief of symptoms with decreased swelling and increased range of motion. Over the past three years, she has had occasional mild flares, improved with increased dosage of her therapies. At baseline, the only evidence of her disease is minimal swelling and stiffness of two toes. Much to the surprise of her ophthalmologist, the uveitis is fully resolved.

A.C., a 3y4m male, with a birth history of 27 wk EGA infant in the NICU on a ventilator for one week, who then had an air embolus leading to severe CNS sequelae. He was now seen for frequent severe respiratory infections including pneumonia, croup, breathing difficulty, sinusitis and frequent otitis media. During the previous six months, he had only 3 weeks total time without illness and had been placed on multiple courses of antibiotics (approx. 5 times in 5-6 months).

After initial presentation with the above history, the 90% AKBA was the core of his treatment plan. Over the following four months, he has had no significant illness. There were two brief episodes of nasal congestion, at which time his mother increased the dosage as directed and symptoms resolved in 2-3 days. His mother came for evaluation by the referral of one of his therapists and was initially skeptical of holistic therapies. She is now very happy and surprised he has gone this long without more significant illness and continues to do quite well.

## Conclusions

Abundant scientific research shows that the AKBA fraction of Boswellic acids is ideally suited to inhibit the 5-lipoxygenase pathway and its resultant pathological inflammatory cascade. The use of boswellia over the centuries attests to therapeutic potential of the gum resin. In recent studies results have been favorable but never spectacular. Raising the level of daily doses of unpurified boswellia extracts, in order to achieve an optimal blood level is difficult from a practical compliance point of view. Even at a standardization level of 5% AKBA, which most market preparations do not have, (if they declare it on the label at all), it would take approx. 16 capsules of 250 mg BSE to achieve a daily dose of 200 mg AKBA per day. The bigger problem, however, would be the concern that concomitantly with the desired AKBA fraction high dosages of the other beta boswellic acids would be ingested. They could potentially exacerbate a hypercoagulable state, particularly in today's world where most patients are presenting with a host of co-morbid conditions.

A highly purified pharmaceutical grade BSE consisting essentially of pure AKBA avoids all the problems and increases exponentially the clinical success rate.

The safety and versatility of this nutritional product will allow its use in numerous pathological conditions that have never been approached in this manner before.

Including inhibitors of 5-LO mediated inflammations in one's routine clinical management should become an established standard of care.

-----

## References

1. Jung SH, Ha YJ, Shim EK, et al. Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator. *Biochemical Journal* 2007;403:243-50.
2. Mathe C, Culioli G, Archier P, Vieillescazes C. High-performance liquid chromatographic analysis of triterpenoids in commercial frankincense. *Chromatographia* 2004;60:493-9.
3. Poeckel D, Werz O. Boswellic acids: Biological actions and molecular targets. *Current Medicinal Chemistry* 2006;13:3359-69.
4. Sudharsan PT, Mythili Y, Selvakumar E, Varalakshmi P. Cardioprotective effect of pentacyclic triterpene, lupeol and its ester on cyclophosphamide-induced oxidative stress. *Human and Experimental Toxicology* 2005;24:313-8.
5. Syrovets T, Büchele B, Krauss C, Laumonier Y, Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF- $\alpha$  induction in monocytes by direct interaction with I $\kappa$ B kinases. *Journal of Immunology* 2005;174:498-506.
6. Sterk V, Büchele B, Simmet T. Simultaneous food intake enhances the bioavailability of frankincense-based phytopharmaceuticals. *Zeitschrift für Phytotherapie* 2005;26:174-80.
7. Sterk V, Büchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. *Planta Medica* 2004;70:1155-60.

8. Borrelli F, Capasso F, Capasso R, et al. Effect of *Boswellia serrata* on intestinal motility in rodents: Inhibition of diarrhoea without constipation. *British Journal of Pharmacology* 2006;148:553-60.
9. Kesava Reddy G, Chandrakasan G, Dhar SC. Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents. *Biochemical Pharmacology* 1989;38:3527-34.
10. Fan AY, Lao L, Zhang R-, et al. Effects of an acetone extract of *Boswellia carterii* Birdw. (*Burseraceae*) gum resin on rats with persistent inflammation. *Journal of Alternative and Complementary Medicine* 2005;11:323-31.
11. Gupta I, Parihar A, Malhotra P, et al. Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *European journal of medical research* 1997;2:37-43.
12. Gupta I, Mahajan A, Gupta V. Salai Guggal-*Boswellia serrata* leukotriene antagonist & inhibitor: Clinical applications. *JK Science* 2002;4:169-73.
13. Gupta I, Gupta V, Parihar A, et al. Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *European journal of medical research* 1998;3:511-4.
14. Griffiths RJ, Smith MA, Roach ML, et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. *Journal of Experimental Medicine* 1997;185:1123-9.
15. Golubic M, Park YS, Lee JH, Jeun SS, Safayhi H, Harwalkar JA. Potent cytotoxic activity of a novel 5-lipoxygenase inhibitor, acetyl-11-keto-boswellic acid (AKBA) on meningioma cells. *Skull Base Surgery* 1999;9:16-7.
16. Reichling J, Schmökel H, Fitzi J, Bucher S, Saller R. Dietary support with *Boswellia* resin in canine inflammatory joint and spinal disease. *Schweizer Archiv fur Tierheilkunde* 2004;146:71-9.
17. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: A double-blind, placebo-controlled, cross-over study. *Journal of Ethnopharmacology* 1991;33:91-5.
18. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of *Boswellia serrata* extract in treatment of osteoarthritis of knee - A randomized double blind placebo controlled trial. *Phytomedicine* 2003;10:3-7.
19. Safayhi H, Sailer E-. Anti-inflammatory actions of pentacyclic triterpenes. *Planta Medica* 1997;63:487-93.
20. Krieglstein CF, Anthoni C, Rijcken EJM, et al. Acetyl-11-keto- $\beta$ -boswellic acid, a constituent of a herbal medicine from *Boswellia serrata* resin, attenuates experimental ileitis. *International Journal of Colorectal Disease* 2001;16:88-95.
21. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of *Boswellia serrata* in patients with chronic colitis. *Planta Medica* 2001;67:391-5.
22. Winking M, Sarikaya S, Rahmanian A, Böker DK. Boswellic acids inhibit the tumor growth - An animal experiment. *Medizinische Welt* 1999;50:515-20.
23. Streffer JR, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. *Neurology* 2001;56:1219-21.
24. Syrovets T, Büchele B, Krauss C, Laumonnier Y, Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF- $\alpha$  induction in monocytes by direct interaction with I $\kappa$ B kinases. *Journal of Immunology* 2005;174:498-506.
25. Tak PP, Firestein GS. NF- $\kappa$ B: A key role in inflammatory diseases. *Journal of Clinical Investigation* 2001;107:7-11.
26. Roy S, Khanna S, Shah H, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of *Boswellia* in microvascular endothelial cells. *DNA and Cell Biology* 2005;24:244-55.
27. Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular responses to inflammation: Inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to antiinflammatory *Boswellia*. *Antioxidants and Redox Signaling* 2006;8:653-60.
28. Poeckel D, Werz O. Boswellic acids: Biological actions and molecular targets. *Current Medicinal Chemistry* 2006;13:3359-69.
29. Sander O, Herborn G, Rau R. Is H15 (Extract of *Boswellia serrata*, 'incense') an efficient supplementation to established drug therapy in RA? - Results of a double blinded pilot trial. *Zeitschrift fur Rheumatologie* 1998;57:11-6.

30. Anthoni C, Laukoetter MG, Rijcken E, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2006;290:
31. Huang M-, Badmaev V, Ding Y, Liu Y, Xie J-, Ho C-. Anti-tumor and anti-carcinogenic activities of triterpenoid,  $\beta$ -boswellic acid. *BioFactors* 2000;13:225-30.
32. Reising K, Meins J, Bastian B, et al. Determination of Boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. *Analytical Chemistry* 2005;77:6640-5.
33. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Potentiation of antinociceptive effect of NSAIDs by a specific lipoxygenase inhibitor, acetyl 11-keto-beta boswellic acid. *Indian Journal of Experimental Biology* 2006;44:128-32.
34. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Analgesic activity of acetyl-11-keto-beta-boswellic acid, a 5-lipoxygenase-enzyme inhibitor. *Indian Journal of Pharmacology* 2005;37:255-6.
35. Hostanska K, Daum G, Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. *Anticancer Research* 2002;22:2853-62.
36. Pungle P, Banavalikar M, Suthar A, Biyani M, Mengi S. Immunomodulatory activity of boswellic acids of *Boswellia serrata* Roxb. *Indian Journal of Experimental Biology* 2003;41:1460-2.
37. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Co-administration of acetyl-11-keto- $\beta$ -boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. *Pharmacology* 2007;79:34-41.
38. Flavin DF. A lipoxygenase inhibitor in breast cancer brain metastases. *Journal of Neuro-Oncology* 2007;82:91-3.
39. Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS, Balakrishnan A. Pure compound from *Boswellia serrata* extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNF $\alpha$ , IL-1 $\beta$ , NO and MAP kinases. *International Immunopharmacology* 2007;7:473-82.
40. Khajuria A, Gupta A, Malik F, et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. *Vaccine* 2007;25:4586-94.
41. Büchele B, Zugmaier W, Estrada A, et al. Characterization of 3 $\alpha$ -Acetyl-11-keto- $\alpha$ -boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. *Planta Medica* 2006;72:1285-9.
42. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Potentiation of antinociceptive effect of NSAIDs by a specific lipoxygenase inhibitor, acetyl 11-keto-beta boswellic acid. *Indian Journal of Experimental Biology* 2006;44:128-32.
43. Sharma ML, Khajuria A, Kaul A, Singh S, Singh GB, Atal CK. Effect of salai guggal ex-*Boswellia serrata* on cellular and humoral immune responses and leucocyte migration. *Agents and Actions* 1988;24:161-4.
44. Kapil A, Moza N. Anticomplementary activity of boswellic acids - An inhibitor of C3-convertase of the classical complement pathway. *International Journal of Immunopharmacology* 1992;14:1139-43.
45. Knaus U, Wagner H. Effects of Boswellic acid of *Boswellia serrata* and other triterpenic acids on the complement system. *Phytomedicine* 1996;3:77-81.
46. Badria FA, Mikhaeil BR, Maatooq GT, Amer MMA. Immunomodulatory triterpenoids from the oleogum resin of *Boswellia carterii* birdwood. *Zeitschrift fur Naturforschung - Section C Journal of Biosciences* 2003;58:505-16.
47. Pandey RS, Singh BK, Tripathi YB. Extract of gum resins of *Boswellia serrata* L. inhibits lipopolysaccharide induced nitric oxide production in rat macrophages along with hypolipidemic property. *Indian Journal of Experimental Biology* 2005;43:509-16.
48. Chevrier MR, Ryan AE, Lee DY-, Zhongze M, Wu-Yan Z, Via CS. *Boswellia carterii* extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. *Clinical and Diagnostic Laboratory Immunology* 2005;12:575-80.
49. Syrovets T, Gschwend JE, Büchele B, et al. Inhibition of I $\kappa$ B kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. *Journal of Biological Chemistry* 2005;280:6170-80.
50. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto- $\beta$ -boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF- $\kappa$ B and NF- $\kappa$ B-regulated gene expression. *Journal of Immunology* 2006;176:3127-40.

51. Ammon HPT, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation of rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of *Boswellia serrata*. *Planta Medica* 1991;57:203-7.
52. Weber C-, Reising K, Müller WE, Schubert-Zsilavec M, Abdel-Tawab M. Modulation of Pgp function by boswellic acids. *Planta Medica* 2006;72:507-13.
53. Poeckel D, Tausch L, George S, Jauch J, Werz O. 3-O-acetyl-11-keto-boswellic acid decreases basal intracellular Ca<sup>2+</sup> levels and inhibits agonist-induced Ca<sup>2+</sup> mobilization and mitogen-activated protein kinase activation in human monocytic cells. *Journal of Pharmacology and Experimental Therapeutics* 2006;316:224-32.
54. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Duan RD. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. *International journal of molecular medicine* 2002;10:501-5.
55. Liu J-, Nilsson A, Oredsson S, Badmaev V, Zhao W-, Duan R-. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. *Carcinogenesis* 2002;23:2087-93.
56. Safayhi H, Rall B, Sailer E-, Ammon HPT. Inhibition by boswellic acids of human leukocyte elastase. *Journal of Pharmacology and Experimental Therapeutics* 1997;281:460-3.
57. Badria FA, Attia HA. Effect of selected natural products, thioproline and pegasys® on hepatic platelet activating factor (PAF) in CCL4-induced hepatic fibrosis in rats. *Saudi Pharmaceutical Journal* 2007;15:96-104.
58. Steinhilber D. 5-lipoxygenase: A target for antiinflammatory drugs revisited. *Current Medicinal Chemistry* 1999;6:71-85.
59. Janssen-Timmen U, Vickers PJ, Wittig U, et al. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. *Proceedings of the National Academy of Sciences of the United States of America* 1995;92:6966-70.
60. Larslversen, Kragballe K, Ziboh VA. Significance of leukotriene-a4 hydrolase in the pathogenesis of psoriasis. *Skin Pharmacology* 1997;10:169-77.
61. Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. *Science* 1983;220:568-75.
62. Hammarberg T, Provost P, Persson B, Rådmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. *Journal of Biological Chemistry* 2000;275:38787-93.
63. Hammarberg T, Rådmark O. 5-Lipoxygenase binds calcium. *Biochemistry* 1999;38:4441-7.
64. Hammarberg T, Zhang Y-, Lind B, Radmark O, Samuelsson B. Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase. *European Journal of Biochemistry* 1995;230:401-7.
65. McMillan RM, Walker ERH. Designing therapeutically effective 5-lipoxygenase inhibitors. *Trends in Pharmacological Sciences* 1992;13:323-30.
66. Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. *Proceedings of the Association of American Physicians* 1999;111:547-59.
67. Wildfeuer A, Neu IS, Safayhi H, et al. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. *Arzneimittel-Forschung/Drug Research* 1998;48:668-74.
68. Altmann A, Poeckel D, Fischer L, Schubert-Zsilavec M, Steinhilber D, Werz O. Coupling of boswellic acid-induced Ca<sup>2+</sup> mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes. *British Journal of Pharmacology* 2004;141:223-32.
69. Safayhi H, Boden SE, Schweizer S, Ammon HPT. Concentration-dependent potentiating and inhibitory effects of *Boswellia* extracts on 5-lipoxygenase product formation in stimulated PMNL. *Planta Medica* 2000;66:110-3.
70. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HPT. Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. *Journal of Pharmacology and Experimental Therapeutics* 1992;261:1143-6.
71. Safayhi H, Sailer E-, Ammon HPT. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. *Molecular Pharmacology* 1995;47:1212-6.
72. Sailer E-, Hoernlein RF, Ammon HPT, Safayhi H. Structure-activity relationships of the nonredox-type non-competitive leukotriene biosynthesis inhibitor acetyl-11 -keto-β-boswellic acid. *Phytomedicine* 1996;3:73-4.

73. Safayhi H, Sailer ER, Ammon HPT. 5-Lipoxygenase inhibition by acetyl-11-keto- $\beta$ -boswellic acid (AKBA) by a novel mechanism. *Phytomedicine* 1996;3:71-2.
74. Poeckel D, Tausch L, Kather N, Jauch J, Werz O. Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca<sup>2+</sup> and differentially interact with platelet-type 12-lipoxygenase. *Molecular Pharmacology* 2006;70:1071-8.
75. Park YS, Lee JH, Harwalkar JA, Bondar J, Safayhi H, Golubic M. Acetyl-11-keto- $\beta$ -boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. *Advances in Experimental Medicine and Biology* 2002;507:387-93.
76. Chen X-, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. *Nature* 1994;372:179-82.
77. Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B<sub>4</sub> augments neutrophil phagocytosis of *Klebsiella pneumoniae*. *Infection and Immunity* 2001;69:2011-6.
78. Mancuso P, Standiford TJ, Marshall T, Peters-Golden M. 5-lipoxygenase reaction products modulate alveolar macrophage phagocytosis of *Klebsiella pneumoniae*. *Infection and Immunity* 1998;66:5140-6.
79. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. *Pulmonary Pharmacology and Therapeutics* 2001;14:3-19.
80. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. *Prostaglandins and Other Lipid Mediators* 2007;83:188-97.
81. Werz O, Steinhilber D. Pharmacological intervention with 5-lipoxygenase: New insights and novel compounds. *Expert Opinion on Therapeutic Patents* 2005;15:505-19.
82. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A<sub>4</sub> hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. *Proceedings of the National Academy of Sciences of the United States of America* 2006;103:8161-6.
83. Chen X-, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. *Nature* 1994;372:179-82.
84. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: Future prospects. *Current Opinion in Lipidology* 2004;15:553-8.
85. Jala VR, Haribabu B. Leukotrienes and atherosclerosis: New roles for old mediators. *Trends in Immunology* 2004;25:315-22.
86. Rådmark O. 5-Lipoxygenase-derived leukotrienes: Mediators also of atherosclerotic inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2003;23:1140-2.
87. Spanbroek R, Habenicht AJR. The Potential Role of Antileukotriene Drugs in Atherosclerosis. *Drug News and Perspectives* 2003;16:485-9.
88. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. *New England Journal of Medicine* 2004;350:29-37.
89. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. *Nature Genetics* 2004;36:233-9.
90. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. *Circulation Research* 2002;91:120-6.
91. Welt K, Fitzl G, Mark B. Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural- morphometric study. *Experimental and Toxicologic Pathology* 2000;52:27-36.
92. Hashimoto H, Miyazawa K, Hagiwara M, Miyasaka K, Nakashima M. Beneficial effects of a new 5-lipoxygenase inhibitor on occlusion- and occlusion-reperfusion-induced myocardial injury. *Arzneimittel-Forschung/Drug Research* 1990;40:126-9.
93. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia: In vivo evidence for 5-lipoxygenase activation. *Circulation* 1992;85:230-6.
94. Haynes Jr. J, Surendra Baliga B, Obiako B, Ofori-Acquah S, Pace B. Zileuton induces hemoglobin F synthesis in erythroid progenitors: Role of the L-arginine-nitric oxide signaling pathway. *Blood* 2004;103:3945-50.
95. Bäck M, Hansson GK. Leukotriene receptors in atherosclerosis. *Annals of Medicine* 2006;38:493-502.
96. Graupera M, GarcíaPagán J, Titos E, et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. *Gastroenterology* 2002;122:387-93.

97. Stanke-Labesque F, Hardy G, Vergnaud S, et al. Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)<sup>27</sup> rats. *Journal of Hypertension* 2002;20:263-72.
98. Stanke-Labesque F, Hardy G, Caron F, Cracowski J-, Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats. *British Journal of Pharmacology* 2003;140:186-94.
99. Doggrel SA. Taking the 20-HETE out of the cardiovascular system: The potential of 20-HETE synthesis inhibitors. *Current Opinion in Investigational Drugs* 2005;6:901-6.
100. Piro M, Giubilato G, Pinnelli M, Giordano Sciacca P, Biasucci LM. Endothelium and inflammation. *Panminerva Medica* 2005;47:75-80.
101. Hao C-, Breyer MD. Physiologic and pathophysiologic roles of lipid mediators in the kidney. *Kidney International* 2007;71:1105-15.
102. Romano M, Clária J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. *FASEB Journal* 2003;17:1986-95.
103. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. *Cancer and Metastasis Reviews* 2001;20:195-206.
104. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. *Integrative Cancer Therapies* 2004;3:349-80.
105. Ye Y-, Liu ES-, Shin VY, Wu WK-, Cho C-. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. *Toxicology* 2004;203:179-88.
106. Ye YN, Wu WKK, Shin VY, Cho CH. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. *European Journal of Pharmacology* 2005;519:52-7.
107. Bunn Jr. PA, Keith RL. The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer. *Clinical Lung Cancer* 2002;3:271-7.
108. Keicher U, Koletzko B, Reinhardt D. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. *European Journal of Clinical Investigation* 1995;25:915-9.
109. Behera AK, Kumar M, Matsuse H, Lockey RF, Mohapatra SS. Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells. *Biochemical and Biophysical Research Communications* 1998;251:704-9.
110. Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. *American Journal of Physiology - Lung Cellular and Molecular Physiology* 2002;282:
111. Dimova-Yaneva DN, Helms PJ. The role of leukotrienes and eosinophil cationic protein in acute respiratory syncytial virus bronchiolitis. *Folia medica* 2003;45:5-11.
112. Lin J, Vambutas A, Haruta A, Paparella MM, Giebink GS, Kim Y. Pneumococcus activation of the 5-lipoxygenase pathway and production of glycoproteins in the middle ear of rats. *Journal of Infectious Diseases* 1999;179:1145-51.
113. Seymour ML, Gilby N, Bardin PG, et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects. *Journal of Infectious Diseases* 2002;185:540-4.
114. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. *British Medical Journal* 2004;328:434-7.
115. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. *American Journal of Respiratory and Critical Care Medicine* 1998;157:1187-94.
116. Drazen JM, Israel E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Editorial. *American Journal of Respiratory and Critical Care Medicine* 1998;158:1697-8.
117. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. *Chest* 2001;119:1533-46.
118. Fahy JV, Kwong Woo Kim, Liu J, Boushey HA. Respiratory pathophysiologic responses: Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. *Journal of Allergy and Clinical Immunology* 1995;95:843-52.

119. Ordoñez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. *American Journal of Respiratory and Critical Care Medicine* 2000;161:1185-90.
120. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma: A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? *American Review of Respiratory Disease* 1993;148:713-9.
121. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. *American Journal of Respiratory and Critical Care Medicine* 1999;160:1532-9.
122. Wenzel SE. Antileukotriene drugs in the management of asthma. *Journal of the American Medical Association* 1998;280:2068-9.
123. Wenzel S. Mechanisms of severe asthma. *Clinical and Experimental Allergy* 2003;33:1622-8.
124. Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. *Journal of Pharmacology and Experimental Therapeutics* 1989;250:598-605.
125. Gelfand EW. Inflammatory mediators in allergic rhinitis. *Journal of Allergy and Clinical Immunology* 2004;114:
126. Steinke JW, Borish L. Leukotriene receptors in rhinitis and sinusitis. *Current Allergy and Asthma Reports* 2004;4:217-23.
127. Barnes PJ. Mechanisms in COPD: Differences from asthma. *Chest* 2000;117:
128. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. *Chest* 2002;121:
129. Garcia C, Boyce BF, Gilles J, et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. *Journal of Bone and Mineral Research* 1996;11:1619-27.
130. Hill PA, Tumber A, Papaioannou S, Meikle MC. The cellular actions of interleukin-11 on bone resorption in vitro. *Endocrinology* 1998;139:1564-72.
131. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. *Current Opinion in Rheumatology* 2003;15:623-7.
132. Murphy ME, Elkins AL, Shrewsbury RP, Sood A, Spielvogel BF, Hall IH. The effects of amine-carboxyborane related derivatives on UMR-106 bone metabolism. *Metal-Based Drugs* 1996;3:31-47.
133. Gallwitz WE, Mundy GR, Lee CH, et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. *Journal of Biological Chemistry* 1993;268:10087-94.
134. Rajendran KG, Chen SY, Sood A, Spielvogel BF, Hall IH. The anti-osteoporotic activity of amine-carboxyboranes in rodents. *Biomedicine and Pharmacotherapy* 1995;49:131-40.
135. Boehm JC, Smietana JM, Sorenson ME, et al. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. *Journal of Medicinal Chemistry* 1996;39:3929-37.
136. Koro O, Furutani K, Hide M, Yamada S, Yamamoto S. Chemical mediators in atopic dermatitis: Involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. *Journal of Allergy and Clinical Immunology* 1999;103:663-70.
137. Talbot SF, Atkins PC, Goetzl EJ, Zweiman B. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. *Journal of Clinical Investigation* 1985;76:650-6.
138. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: Recent data, new understanding of the treatments. *European Journal of Dermatology* 2004;14:4-12.
139. Leung DYM. Atopic dermatitis: The skin as a window into the pathogenesis of chronic allergic diseases. *Journal of Allergy and Clinical Immunology* 1995;96:302-19.
140. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *Journal of Clinical Investigation* 2004;113:651-7.
141. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. *Annals of Allergy, Asthma and Immunology* 1999;83:548-52.
142. Zouboulis CC, Nestoris S, Adler YD, et al. A new concept for acne therapy: A pilot study with zileuton, an oral 5-lipoxygenase inhibitor [4]. *Archives of Dermatology* 2003;139:668-70.
143. Ikai K, Okano H, Horiguchi Y, Sakamoto Y. Leukotriene A4 hydrolase in human skin. *Journal of Investigative Dermatology* 1994;102:253-7.
144. Iversen L, Kristensen P, Grøn B, Ziboh VA, Kragballe K. Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. *Archives of Dermatological Research* 1994;286:261-7.

145. Koreck A, Pivarcsi A, Dobozy A, Kemény L. The role of innate immunity in the pathogenesis of acne. *Dermatology* 2003;206:96-105.
146. Kragballe K, Desjarlais L, Voorhees JJ. Leukotrienes B<sub>4</sub>, C<sub>4</sub> and D<sub>4</sub> stimulate DNA synthesis in cultured human epidermal keratinocytes. *British Journal of Dermatology* 1985;113:43-52.
147. Sheftell F, Rapoport A, Weeks R, Walker B, Gammerman I, Baskin S. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. *Headache* 2000;40:158-63.
148. Chan-Ling T, Hughes S, Baxter L, et al. Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: A model for CNS aging. *Microcirculation* 2007;14:63-76.
149. Haitchi HM, Holgate ST. New strategies in the treatment and prevention of allergic diseases. *Expert Opinion on Investigational Drugs* 2004;13:107-24.
150. Pynaert G, Grooten J, Van Deventer SJH, Peppelenbosch MP. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. *Molecular Medicine* 1999;5:685-92.
151. Vila L, Sanz ML, Sánchez G, et al. Study of the in vitro sulphidoleukotriene production in food-allergic patients. *Journal of Investigational Allergology and Clinical Immunology* 2001;11:247-54.
152. Di Lorenzo G, Pacor ML, Vignola AM, et al. Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. *Allergy: European Journal of Allergy and Clinical Immunology* 2002;57:1180-6.
153. Schaub RG, Yamashita A. Leukocyte mediated vein injury and thrombosis is reduced by a lipoxygenase inhibitor. *Experimental and Molecular Pathology* 1986;45:343-53.
154. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. *British Journal of Clinical Pharmacology* 2004;58:587-600.
155. Park S, Han S-, Lee K-, Park KH, Cho SW, Hahm K-. 5-LOX inhibitor modulates the inflammatory responses provoked by *Helicobacter pylori* infection. *Helicobacter* 2007;12:49-58.
156. Park S, Yeo M, Jin J-, et al. Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in *Helicobacter pylori*-infected gastric epithelial cells. *Digestive Diseases and Sciences* 2007;52:973-82.
157. Kiela PR, Midura AJ, Kuscuglu N, et al. Effects of *Boswellia serrata* in mouse models of chemically induced colitis. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2005;288:
158. Safayhi H, Boden SE, Schweizer S, Ammon HPT. Concentration-dependent potentiating and inhibitory effects of *Boswellia* extracts on 5-lipoxygenase product formation in stimulated PMNL. *Planta Medica* 2000;66:110-3.
159. Poeckel D, Tausch L, Altmann A, et al. Induction of central signalling pathways and select functional effects in human platelets by  $\beta$ -boswellic acid. *British Journal of Pharmacology* 2005;146:514-24.
160. Hoernlein RF, Orlikowsky T, Zehrer C, et al. Acetyl-11-keto- $\beta$ -boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. *Journal of Pharmacology and Experimental Therapeutics* 1999;288:613-9.
161. Shao Y, Ho C-, Chin C-, Badmaev V, Ma W, Huang M-. Inhibitory activity of boswellic acids from *Boswellia serrata* against human leukemia HL-60 cells in culture. *Planta Medica* 1998;64:328-31.
162. Jing Y, Nakajo S, Xia L, et al. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. *Leukemia Research* 1999;23:43-50.
163. Jing Y, Xia L, Han R. Growth inhibition and differentiation of promyelocytic cells (HL-60) induced by BC-4, an active principle from *Boswellia carterii* birdw. *Chinese Medical Sciences Journal* 1992;7:12-5.
164. Zhao W, Entschladen F, Liu H, et al. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. *Cancer Detection and Prevention* 2003;27:67-75.
165. Xiao J, Liu X-, Yan D-, Liu R-, Zhang W, Tan G-. Effects of *Boswellia carterii* volatile oils on proliferation and apoptosis of liver cancer cell SMMC-7721. *Chinese Journal of Natural Medicines* 2007;5:68-72.
166. Liu X, Qi ZH. Experimental study on Jurkat cell apoptosis induced by *Boswellia carterii* Birdw extractive. *Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University* 2000;25:241-4.
167. Syrovets T, Büchele B, Gedig E, Slupsky JR, Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II $\alpha$ . *Molecular Pharmacology* 2000;58:71-81.
168. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R. Pharmacokinetics study of 11-Keto  $\beta$ -Boswellic Acid. *Phytomedicine* 2004;11:255-60.

169. Rajnikant, Gupta VK, Rangari VD, Bapat SR, Agarwal RB, Gupta R. Crystallographic analysis of acetyl  $\beta$ -boswellic acid. *Crystal Research and Technology* 2001;36:93-100.
170. Platel K, Srinivasan K. Studies on the influence of dietary spices on food transit time in experimental rats. *Nutrition Research* 2001;21:1309-14.
171. Platel K, Srinivasan K. Stimulatory influence of select spices on bile secretion in rats. *Nutrition Research* 2000;20:1493-503.
172. Platel K, Srinivasan K. Influence of dietary spices and their active principles on pancreatic digestive enzymes in albino rats. *Nahrung - Food* 2000;44:42-6.
173. Bachert C, Lange B. Histamine and leukotrienes in allergic rhinitis. *Allergologie* 1999;22:492-507.
174. Barnes NC, Smith LJ. Biochemistry and physiology of the leukotrienes. *Clinical Reviews in Allergy and Immunology* 1999;17:27-42.
175. Khoury P, Baroody FM, Klemens JJ, Thompson K, Naclerio RM. Effect of montelukast on bacterial sinusitis in allergic mice. *Annals of Allergy, Asthma and Immunology* 2006;97:329-35.
176. Lieberman P. Management of allergic rhinitis with a combination antihistamine/antiinflammatory agent. *Journal of Allergy and Clinical Immunology* 1999;103:
177. Naclerio RM. Pathophysiology of perennial allergic rhinitis. *Allergy: European Journal of Allergy and Clinical Immunology, Supplement* 1997;52:7-13.
178. Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: Multi-functional mediators in allergic rhinitis. *Clinical and Experimental Allergy* 2006;36:689-703.
179. Pynaert G, Grooten J, Van Deventer SJH, Peppelenbosch MP. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. *Molecular Medicine* 1999;5:685-92.
180. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. *American Journal of Respiratory and Critical Care Medicine* 1997;155:1856-63.
181. Frank A, Unger M. Analysis of frankincense from various *Boswellia* species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. *Journal of Chromatography A* 2006;1112:255-6

## **ADDENDUM- Additional Research papers 2009-2011**

### **Evaluation of systemic administration of *Boswellia papyrifera* extracts on spatial memory retention in male rats**

#### Abstract

Time-dependent effects of ethanolic extract of *Boswellia papyrifera*, administered systemically, on spatial memory retention in the Morris water maze were investigated in male rats. A total extract of *Boswellia papyrifera* (300 mg/kg) was administered every eight hours to three groups of rats by gavage for 1, 2 and 4 weeks. In a separate set of experiments, three doses of a fraction of the extract, called the boswellic acids (100, 200 and 300 mg/kg) were administered by gavage to three groups of rats three times a day for 2 weeks. Following these applications, animals were trained for 4 days. Behavioral testing for evaluation of spatial memory retention was performed 48 h after completion of training. *Boswellia papyrifera* extracts and boswellic acids caused a significant reduction in escape latency and distance traveled but had no influence on swimming speed. These findings provide evidence that *Boswellia papyrifera* extracts affect spatial memory retention irrespective of the treatment period. In addition our data show that systemic administration of the boswellic acids fraction enhanced spatial memory retention in a dosedependent manner. These improving effects may be due to some extent to the interactions of these products with inflammatory mediators, neurotransmitter signaling cascades or protein kinase pathways in the brain. (184)

## **Acetyl-11-keto-b-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression**

### **Abstract**

Ninety percent of cancer-mediated deaths are due to metastasis of the tumor; however, the mechanisms controlling metastasis remain poorly understood. Thus, no therapy targeting this process has yet been approved. Chemokines and their receptors are mediators of chronic inflammation and have been linked to the metastasis of numerous cancers. More recently, the Cysteine X Cysteine (CXC) chemokine receptor 4 (CXCR4) has emerged as a key mediator of tumor metastasis; therefore, identification of inhibitors of this receptor has the potential to abrogate metastasis. In this report, we demonstrate that acetyl-11-keto-b-boswellic acid (AKBA), a component of the therapeutic plant *Boswellia serrata*, can downregulate CXCR4 expression in pancreatic cancer cells. The reduction in CXCR4 induced by this terpenoid was found to be cell-type specific, as its expression was also abrogated in leukemia, myeloma and breast cancer cell lines. Neither proteasome inhibitors nor lysosomal stabilization could prevent the AKBA-induced reduction in CXCR4 expression. This downregulation occurred at the transcriptional level. Suppression of CXCR4 by AKBA was accompanied by the inhibition of pancreatic cancer cell invasion, which is induced by CXCL12, the ligand for CXCR4. In addition, abrogation of the expression of chemokine receptor by AKBA was found in human pancreatic tissues from orthotopic animal model. AKBA also abolished breast tumor cell invasion, and this effect correlated with the disappearance of both the CXCR4 messenger RNA and CXCR4 protein. Overall, our results show that AKBA is a novel inhibitor of CXCR4 expression and, thus, has the potential to suppress the invasion and metastasis of cancer cells. (185)

## **Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-b-boswellic acid from *Boswellia serrata***

### **Abstract**

**Background:** Boswellic acids are pentacyclic triterpenes, which are produced in plants belonging to the genus *Boswellia*. Boswellic acids appear in the resin exudates of the plant and it makes up 25-35% of the resin. Boswellic acid, 11-keto-b-boswellic acid and acetyl-11-keto-b-boswellic acid have been implicated in apoptosis of cancer cells, particularly that of brain tumors and cells affected by leukemia or colon cancer. These molecules are also associated with potent antimicrobial activities. The present study describes the antimicrobial activities of boswellic acid molecules against 112 pathogenic bacterial isolates including ATCC strains. Acetyl-11-keto-b-boswellic acid (AKBA), which exhibited the most potent antibacterial activity, was further evaluated in time kill studies, postantibiotic effect (PAE) and biofilm susceptibility assay. The mechanism of action of AKBA was investigated by propidium iodide uptake, leakage of 260 and 280 nm absorbing material assays.

**Results:** AKBA was found to be the most active compound showing an MIC range of 2-8  $\mu\text{g/ml}$  against the entire gram positive bacterial pathogens tested. It exhibited concentration dependent killing of *Staphylococcus aureus* ATCC 29213 up to  $8 \times \text{MIC}$  and also demonstrated postantibiotic effect (PAE) of 4.8 h at  $2 \times \text{MIC}$ . Furthermore, AKBA inhibited the formation of biofilms generated by *S. aureus* and *Staphylococcus epidermidis* and also reduced the preformed biofilms by these bacteria. Increased uptake of propidium iodide and leakage of 260 and 280 nm absorbing material by AKBA treated cells of *S. aureus* indicating that the antibacterial mode of action of AKBA probably occurred via disruption of microbial membrane structure.

Conclusions: This study supported the potential use of AKBA in treating *S. aureus* infections. AKBA can be further exploited to evolve potential lead compounds in the discovery of new anti-Gram-positive and anti-biofilm agents. (186)

### **Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract**

#### Abstract

There is significant number of evidences suggesting the anti-inflammatory properties of gum resin extracts of *Boswellia serrata* containing 3-O-acetyl-11-ketob-boswellic acid (AKBA) and their promising potential as therapeutic interventions against inflammatory diseases such as osteoarthritis (OA). Unfortunately, the poor bioavailability of AKBA following oral administration might limit the anti-inflammatory efficacy of standardized *Boswellia* extract(s). To address this issue, we describe a novel composition called Aflapin, which contains *B. serrata* extract enriched in AKBA and non-volatile oil portion of *B. serrata* gum resin. Our observations show that the availability of AKBA in systemic circulation of experimental animals is increased by 51.78% in Aflapin-supplemented animals, in comparison with that of 30% AKBA standardized extract or BE-30 (5-Loxin<sub>®</sub>). Consistently, Aflapin confers better antiinflammatory efficacy in Freund's Complete Adjuvant (FCA)-induced inflammation model of Sprague–Dawley rats. Interestingly, in comparison with BE-30, Aflapin<sub>®</sub> also provides significantly better protection from IL-1 $\beta$ -induced death of human primary chondrocytes and improves glycosaminoglycans production in human chondrocytes. In Tumor necrosis factor alpha (TNF $\alpha$ )-induced human synovial cells, the inhibitory potential of Aflapin (IC<sub>50</sub> 44.736 ng/ml) on matrix metalloproteinase-3 (MMP-3) production is 14.83% better than that of BE-30 (IC<sub>50</sub> 52.528 ng/ml). In summary, our observations collectively suggest that both the *Boswellia* products, BE-30 (5-Loxin<sub>®</sub>) and Aflapin, exhibit powerful anti-inflammatory efficacy and anti-arthritic potential. In particular, in comparison with BE-30, Aflapin provides more potential benefits in recovering articular cartilage damage or protection from proteolytic degradation due to inflammatory insult in arthritis such as osteoarthritis or rheumatoid arthritis. (187)

### **Natural anti-inflammatory products and leukotriene inhibitors as complementary therapy for bronchial asthma**

#### Abstract

Objective: To assess the efficacy of a combination of frankincense (*Boswellia serrata*), licorice root (*Glycyrrhiza glabra*) and Tumeric root (*Curcuma longa*) as natural leukotriene inhibitors, antiinflammatory and antioxidant products respectively in controlling bronchial asthma. Subjects and methods: The study comprised 63 patients with bronchial asthma that are further subdivided into two groups .Group 1 receiving oral capsule (combined herb) in a soft-gelatin capsule 3 times daily for 4 weeks and group 2 receiving placebo. Plasma leukotriene C<sub>4</sub> (LTC<sub>4</sub>), nitric oxide (NO) and malondialdehyde (MDA) levels were measured and pulmonary function was also assessed in all patients enrolled in the study. Results: There was a statistically significant decrease in the plasma levels of LTC<sub>4</sub>, (MDA), and NO in target therapy group when compared with placebo group.

Conclusion: The used extract contained *Boswellia serrata*, *Curcuma longa* and *Glycyrrhiza* has a pronounced effect in the management of bronchial asthma.(191)

### **The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study)**

Abstract

Increasing evidences implicate impairment of axonal integrity in mechanisms underlying neurodegenerative disorders. Beta-boswellic acid (BBA) is the major component of *Boswellia serrata* gum. This resin has long been used in Ayurveda (India's traditional medicine) to prevent amnesia. In this study, the effect of BBA was examined on neurites outgrowth and branching as well as on polymerization dynamics of tubulin. The morphometric parameters (axonal length and neuritis branching) were examined microscopically after treating the hippocampal cells with BBA. Also the assembly process of tubulin was assessed using UV/V is spectrophotometer through following of absorbance at 350 nm. The results revealed that BBA could significantly enhance neurite outgrowth, branching, and tubulin polymerization dynamics. The obtained results suggest that enhancing effect of BBA on microtubule polymerization kinetics might be the origin of increasing axonal outgrowth and branching.(193)

### **Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense**

Abstract

Frankincense, the gum resin derived from *Boswellia* species, showed anti-inflammatory efficacy in animal models and in pilot clinical studies. Boswellic acids (BAs) are assumed to be responsible for these effects but their anti-inflammatory efficacy *in vivo* and their molecular modes of action are incompletely understood. A protein fishing approach using immobilized BA and surface plasmon resonance (SPR) spectroscopy were used to reveal microsomal prostaglandin E2 synthase-1 (mPGES1) as a BA-interacting protein. Cell-free and cell-based assays were applied to confirm the functional interference of BAs with mPGES1. Carrageenan-induced mouse paw oedema and rat pleurisy models were utilized to demonstrate the efficacy of defined BAs *in vivo*. Human mPGES1 from A549 cells or *in vitro*-translated human enzyme selectively bound to BA affinity matrices and SPR spectroscopy confirmed these interactions. BAs reversibly uppressed the transformation of prostaglandin (PG)H2 to PGE2 mediated by mPGES1 (IC50 = 3–10 mM). Also, in intact A549 cells, BAs selectively inhibited PGE2 generation and, in human whole blood, b-BA reduced lipopolysaccharide-induced PGE2 biosynthesis without affecting formation of the COX-derived metabolites 6-keto PGF1a and thromboxane B2. Intraperitoneal or oral administration of b-BA (1 mg·kg-1) suppressed rat pleurisy, accompanied by impaired levels of PGE2 and b-BA (1 mg·kg-1, given i.p.) also reduced mouse paw oedema, both induced by carrageenan. CONCLUSIONS: Suppression of PGE2 formation by BAs via interference with mPGES1 contribute to the anti-inflammatory effectiveness of BAs and of frankincense, and may constitute a biochemical basis for their anti-inflammatory properties. (198)

### **Frankincense: A Systematic Review**

ABSTRACT

Objective To assess evidence from randomised clinical trials about the effectiveness of extracts of *Boswellia serrata* (frankincense). Design Systematic review. Data sources Electronic searches on Medline, Embase, Cinahl, Amed, and Cochrane Library. Hand searches of conference proceedings, bibliographies, and departmental files. Review methods All randomised clinical trials of *B serrata* extract as a treatment for any human medical condition were included and studies of *B serrata* preparations combined with other ingredients were excluded. Titles and

abstracts of all retrieved articles were read and hard copies of all relevant articles were obtained. Selection of studies, data extraction and validation were done by the author. The Jadad score was used to evaluate the methodological quality of all included trials. Results Of 47 potentially relevant studies, seven met all inclusion criteria (five placebo controlled, two with active controls). The included trials related to asthma, rheumatoid arthritis, Crohn's disease, osteoarthritis, and collagenous colitis. Results of all trials indicated that B serrata extracts were clinically effective. Three studies were of good methodological quality. No serious safety issues were noted. Conclusions: The evidence for the effectiveness of Boswellia is encouraging but not compelling. (199)

### **A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee**

**Introduction** 5-Loxin® is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-Loxin® in the treatment of osteoarthritis (OA) of the knee. **Methods** Seventy-five OA patients were included in the study. The patients received either 100 mg (n = 25) or 250 mg (n =25) of 5-Loxin® daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients. Measurement of a battery of biochemical parameters in serum and haematological parameters, and urine analysis were performed to evaluate the safety of 5-Loxin® in OA patients. **Results** Seventy patients completed the study. At the end of the study, both doses of 5-Loxin® conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin® as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3. In comparison with placebo, the safety parameters were almost unchanged in the treatment groups. **Conclusion** 5-Loxin® reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin® may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.(201)

### **References**

182. Abdel-Tawab M, Werz O, Schubert-Zsilavec M. Boswellia serrata: An overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. *Clin Pharmacokinet.* 2011;50(6):349-369.
183. Holtmeier W, Zeuzem S, Prei J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy. *Inflamm Bowel Dis.* 2011;17(2):573-582.

184. Mahmoudi A, Hosseini-Sharifabad A, Monsef-Esfahani HR, et al. Evaluation of systemic administration of *Boswellia papyrifera* extracts on spatial memory retention in male rats. *Journal of Natural Medicines*. 2011;1-7.
185. Park B, Sung B, Yadav VR, Cho S-, Liu M, Aggarwal BB. Acetyl-11-keto- $\beta$ -boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. *International Journal of Cancer*. 2011;129(1):23-33.
186. Raja AF, Ali F, Khan IA, et al. Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto- $\beta$ -boswellic acid from *Boswellia serrata*. *BMC Microbiology*. 2011;11.
187. Sengupta K, Kolla JN, Krishnaraju AV, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel *Boswellia serrata* extract. *Mol Cell Biochem*. 2011;1-9.
188. Venkatesha SH, Berman BM, Moudgil KD. Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. *Bioorganic and Medicinal Chemistry*. 2011;19(1):21-29.
189. Calzavara-Pinton P, Zane C, Facchinetti E, Capezzer R, Pedretti A. Topical Boswellic acids for treatment of photoaged skin. *Dermatologic Therapy*. 2010;23(SUPPL. 1).
190. Clark CE, Arnold E, Lasserson TJ, Wu T. Herbal interventions for chronic asthma in adults and children: A systematic review and meta-analysis. *Primary Care Respiratory Journal*. 2010;19(4):307-314.
191. Houssen ME, Ragab A, Mesbah A, et al. Natural anti-inflammatory products and leukotriene inhibitors as complementary therapy for bronchial asthma. *Clin Biochem*. 2010;43(10-11):887-890.
192. Karima O, Riaz G, Yousefi R, Movahedi AAM. The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study). *Neurological Sciences*. 2010;1-6.
193. Patwardhan SK, Bodas KS, Gundewar SS. Coping with arthritis using safer herbal options. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2010;2(1):1-11.
194. Qurishi Y, Hamid A, Zargar MA, Singh SK, Saxena AK. Potential role of natural molecules in health and disease importance of boswellic acid. *Journal of Medicinal Plant Research*. 2010;4(25):2778-2785.
195. Sharma A, Bhatia S, Kharya MD, et al. Anti-inflammatory and analgesic activity of different fractions of *Boswellia serrata*. *International Journal of Phytomedicine*. 2010;2(1):94-99.
196. Sharma A, Gupta NK, Dixit VK. Complexation with phosphatidyl choline as a strategy for absorption enhancement of boswellic acid. *Drug Deliv*. 2010;17(8):587-595.
197. Siemoneit U, Pergola C, Jazzar B, et al. On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance. *Eur J Pharmacol*. 2009;606(1-3):246-254.
198. Chrubasik S. Effectiveness of *Boswellia serrata* extract supplemented with a synthetic lipoxygenase inhibitor in the treatment of knee osteoarthritis. Commentary. *Focus on Alternative and Complementary Therapies*. 2008;13(4):267-268.
199. Ernst, E. Frankincense Systematic Review. *BMJ* 2008;337:a2813
200. Ota M, Houghton PJ. Boswellic acids with acetylcholinesterase inhibitory properties from frankincense. *Natural Product Communications*. 2008;3(1):21-26.
201. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. *Arthritis Research and Therapy*. 2008;10(4).
202. Singh S, Khajuria A, Taneja SC, Johri RK, Singh J, Qazi GN. Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders. *Phytomedicine*. 2008;15(6-7):400-407.
203. Singh S, Khajuria A, Taneja SC, et al. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from *Boswellia serrata*, in rats. *Phytomedicine*. 2008;15(6-7):408-415.

204. Yuan H-, Kong F, Wang X-, Young CYF, Hu X-, Lou H-. Inhibitory effect of acetyl-11-keto- $\beta$ -boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. *Biochem Pharmacol.* 2008;75(11):2112-2121.
205. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. *Phytotherapy Research.* 2007;21(7):675-683.
206. Madisch A, Miehke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. *Int J Colorectal Dis.* 2007;22(12):1445-1451.
207. Houssen ME, Ragab A, Mesbah A, et al. Natural anti-inflammatory products and leukotriene inhibitors as complementary therapy for bronchial asthma. *Clin Biochem.*